Some price transparency tools aim to provide real-time healthcare information to patients’ on their out-of-pocket costs, deductibles, and information on variation between certain physicians and providers. As important as this information is, tools of this type are not widely available. The panelists also discussed the relevance of the available information, and whether it is making a difference for consumers, as well as for providers in terms of contracting and overall expenditures.
Castlight Health and Truven Health Analytics, among others, offer price transparency tools that allow patients to track their out-of-pocket costs, deductibles, and other relevant information in real time. Such technology is a big step forward, explains Ateev Mehrotra, MD, MPH, associate professor of health care policy and medicine at Harvard Medical School and hospitalist at Beth Israel Deaconess Medical Center. Yet, says Dr Mehrotra, survey data show “the vast majority of people…trying to shop for care aren’t using such websites because their employer doesn’t have them available or they don’t even know about it….It just doesn’t really work.”
To the extent possible, some of these price transparency tools are designed to couple the costs and the out-of-pocket costs with quality, explains Arthur Vercillo, MD, FACS, a surgeon and regional president of Excellus Blue Cross Blue Shield. Dr Vercillo asks, “What if having an arthroscopy is going to be 20% less in one place versus another, but the infection rate is 10% higher?” This type of data is what truly matters to patients.
Francois de Brantes, MS, MBA, executive director, Healthcare Incentives Improvement Institute, believes pricing transparency has truly changed negotiations with providers and affected spending. Available data are making a difference in terms of contracting and overall expenditures, he says, and although the amount of data as well as their relevance will vary, “The core of the information exists.” Mr de Brantes explains how state legislations are trying free up information so entrepreneurs can then make tools readily available to consumers as well as providers.
There is a potential downside of having a lot of previously unavailable information, says Dr Mehrotra, who is “just struck with the knowledge that the hospital down the street is getting paid 20% more than I.” Dr Vercillo acknowledges that “Providers are all curious as to where they stand relative to their peers in terms of not just cost, but quality also,” and will eventually use those data to their advantage.
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More